Correlation Between Hysteroscopic Diagnosis of Endometrial Hyperplasia and Histopathological Examination

Sponsor
University of Campania "Luigi Vanvitelli" (Other)
Overall Status
Completed
CT.gov ID
NCT03917147
Collaborator
(none)
435
1
11
39.5

Study Details

Study Description

Brief Summary

A prospective cohort study at a Tertiary University Hospital. From January to December 2018, we enrolled women with the following criteria: abnormal uterine bleeding in post-menopause, endometrial thickening in pre-or post-menopause; tamoxifen usage. Patients underwent office hysteroscopy with a 5-mm continuous-flow hysteroscope and endometrial biopsies were taken using miniaturized instruments. Senior operators had to foresee histopathological diagnosis using a questionnaire. Histopathological examination was conducted to confirm the diagnosis.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Office Hysteroscopy

Detailed Description

Patient underwent the procedure after the menstrual phase (day 6 to 10) of a spontaneous menstrual cycle. All the procedures were performed by means of a continuous flow small-diameter hysteroscope with oval profile (maximum diameter 5 mm, minimum diameter 3.9 mm) (Bettocchi Office Hysteroscope size 5, Karl Storz GmbH & Co., Tuttlingen, Germany) fitted with a 30-degree telescope of 2.9 mm gauge, using the vaginoscopic approach, without tenaculum and speculum, and using saline solution as distending medium at 90-100 mmHg pressure generated by a pneumatic cuff and measured by means of a manometer; the biopsies were performed with the "punch" or "grasp" technique using a 5 Fr grasping forceps inserted through the operating channel of the hysteroscope. In case of small intrauterine pathologies, they were easily removed by means of a straight bipolar electrode active by an electrosurgical generator (Versapoint II; Gynecare, Ethicon) used to provide a 50W power for the mildest vapour cutting mode (VC3).

The hysteroscopic diagnosis of hyperplasia was based on one or more of the following findings: (1) focal or diffuse, papillary or polypoid, endometrial thickening, (2) Abnormal vascular patterns; (3) evidence of glandular cysts; (4) abnormal architecture features of glandular outlets (thickening, irregular gland density, dilatation). Although no consensus or RCTs showed agreement in describing objective criteria for EH, several trials agreed on the previous morphologic evaluation. [8].

The procedures were taken by three senior gynaecologists (P.D.F, L.C., N.C) whose expertise and skills were equivalent. After every procedure, surgeons were asked to propose a suggestive histological categorization of the clinical diagnosis by means of a questionnaire, in order to standardize the assessment. The questionnaire was made of a progressive number which identified the biopsy and a multiple-choice question. Operators were asked to choose one from the following answers: Benign (including atrophic endometrium, proliferative endometrium, endometrial polyp/s); Endometrial Hyperplasia (simple or complex hyperplasia); Atypical Hyperplasia/Carcinoma (including atypical endometrial hyperplasia and adenocarcinoma) Biopsied histological samples were sent for histopathological analysis. The histopathological examination of all the specimens was performed at the Pathology Unit of University of Campania "Luigi Vanvitelli". Three senior gynecopathologists (INS), with the same skills and expertise, were addressed to evaluate all the biopsies

Study Design

Study Type:
Observational
Actual Enrollment :
435 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Correlation Between Hysteroscopic Diagnosis of Endometrial Hyperplasia and Histopathological Examination: a Prospective Cohort Study
Actual Study Start Date :
Jan 8, 2018
Actual Primary Completion Date :
Oct 18, 2018
Actual Study Completion Date :
Dec 9, 2018

Arms and Interventions

Arm Intervention/Treatment
AUB in Post-Menopause

Abnormal Uterine Bleeding (AUB) in Post-Menopause

Procedure: Office Hysteroscopy
Patients underwent office hysteroscopy with a 5-mm continuous-flow hysteroscope and endometrial biopsies were taken using miniaturized instruments. Histopathological examination was conducted to confirm the diagnosis.

Endometrial Thickening in post-menopause

Ultrasonographic detection of Thickened Endometrium in post-menopause

Procedure: Office Hysteroscopy
Patients underwent office hysteroscopy with a 5-mm continuous-flow hysteroscope and endometrial biopsies were taken using miniaturized instruments. Histopathological examination was conducted to confirm the diagnosis.

Endometrial Thickening in pre-menopause

Ultrasonographic detection of Thickened Endometrium in pre-menopause

Procedure: Office Hysteroscopy
Patients underwent office hysteroscopy with a 5-mm continuous-flow hysteroscope and endometrial biopsies were taken using miniaturized instruments. Histopathological examination was conducted to confirm the diagnosis.

Pharmacological history of Tamoxifen-related therapy regimens

Patients who had been treated with Tamoxifen

Procedure: Office Hysteroscopy
Patients underwent office hysteroscopy with a 5-mm continuous-flow hysteroscope and endometrial biopsies were taken using miniaturized instruments. Histopathological examination was conducted to confirm the diagnosis.

Outcome Measures

Primary Outcome Measures

  1. Sensitivity For Endometrial Hyperplasia [12 months]

  2. Correlation between histopathological and cllinical diagnosis for Endometrial Hyperplasia [12 months]

Secondary Outcome Measures

  1. Negative Predictive value [12 months]

  2. Positive Predictive value [12 months]

  3. Likelihood ratio [12 months]

  4. Positive and negative post test probability [12 months]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 60 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • abnormal uterine bleeding in post-menopause

  • ultrasonographic detection of endometrial thickening in pre-menopause

  • ultrasonographic detection of endometrial thickening in post-menopause

  • follow-up after Tamoxifen-based therapy regimens

Exclusion Criteria:
  • severe urinary symptoms

  • history of severe comorbidities (autoimmune disorders, chronic diseases and severe cardiac disease)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Woman, Child and General and Specialized Surgery, University of Campania "Luigi Vanvitelli" Naples Italy 80131

Sponsors and Collaborators

  • University of Campania "Luigi Vanvitelli"

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Prof. Pasquale De Franciscis, Associate Professor, University of Campania "Luigi Vanvitelli"
ClinicalTrials.gov Identifier:
NCT03917147
Other Study ID Numbers:
  • N.592
First Posted:
Apr 16, 2019
Last Update Posted:
Apr 16, 2019
Last Verified:
Apr 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Keywords provided by Prof. Pasquale De Franciscis, Associate Professor, University of Campania "Luigi Vanvitelli"
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 16, 2019